Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741858 · ClinicalTrials.gov registry record · Phase 3
Duragen Versus Duraguard in Chiari Surgery
A Phase 3 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00741858 is a Phase 3 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 34 participants.
The verdict
NCT00741858, a Phase 3 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
The study evaluates two materials used for duraplasty of the posterior cranial fossa in treatment of Chiari malformation. One material (DuraGen) is a non-suturable collagen matrix that is applied over the defect if brain coverings (dura); the other (DuraGuard) is made out of bovine pericardium and has to be sutured during application. The study compares these two materials used for duraplasty of patients undergoing Chiari surgery in a prospective randomized fashion to check the rate of surgical complications associated with each material, patient's outcomes, length of surgery and the hospital stay, etc.
Interventions
- PROCEDURE Duragen duraplasty
- PROCEDURE Duraguard duraplasty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2003-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741858
The ClinicalTrials.gov registry entry for NCT00741858 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Duragen duraplasty is the first listed.
NCT00741858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741858 about?
NCT00741858 is a clinical study titled "Duragen Versus Duraguard in Chiari Surgery". The study evaluates two materials used for duraplasty of the posterior cranial fossa in treatment of Chiari malformation. One material (DuraGen) is a non-suturable collagen matrix that is applied over the defect if brain coverings (dura); the other (DuraGuard) is made out of bovine pericardium and h...
What is the current status of trial NCT00741858?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2003-04. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00741858?
The interventions under investigation include: Duragen duraplasty (PROCEDURE), Duraguard duraplasty (PROCEDURE).
Who is sponsoring clinical trial NCT00741858?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.